To include your compound in the COVID-19 Resource Center, submit it here.

Tularik drops T611 and T64

TLRK discontinued development of T611, a selective inhibitor of a cytomegalovirus (CMV) enzyme, and T64 anti-cancer agent

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE